Pharsight

Halozyme Therap patents expiration

1. Hylenex Recombinant patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767429 HALOZYME THERAP Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Sep, 2027

(3 years from now)

Drugs and Companies using HYALURONIDASE RECOMBINANT HUMAN ingredient

Market Authorisation Date: 02 December, 2005

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

HYLENEX RECOMBINANT family patents

Family Patents